Nicotinic acetylcholine receptor alpha-6 beta-3 (nAChR alpha6beta3) (nAChR alpha6beta3)

The Nicotinic acetylcholine receptor alpha-6 beta-3 (nAChR alpha6beta3) is a specific subunit assembly of the pentameric nicotinic ligand-gated ion channel family, predominantly expressed in catecholaminergic neurons of the central nervous system (UniProt P43681, P32297). These receptors are highly localized in the substantia nigra and ventral tegmental area, where they play a pivotal role in modulating dopamine release in the striatum (Gotti et al., 2010, Nature Reviews Neuroscience). Due to this restricted expression, alpha6beta3-containing receptors are considered high-value targets for treating Parkinson's disease, as they are selectively lost during dopaminergic neurodegeneration (Quik et al., 2011, Trends in Pharmacological Sciences). They are also heavily implicated in the reinforcing effects of nicotine, making them a target for smoking cessation and substance abuse therapies (Yang et al., 2009, Journal of Biological Chemistry). Pharmacological targeting of this receptor aims to achieve high selectivity to avoid the side effects associated with more ubiquitous nicotinic subtypes, such as alpha4beta2 or alpha3beta4. Current research focuses on developing small molecules and peptide toxins, like alpha-conotoxins, that can distinguish the unique binding interface of the alpha6 subunit (PubMed: 19144818).

Other names

CHRNA6/CHRNB3 complexAlpha6-beta3 nicotinic receptorNeuronal acetylcholine receptor subunit alpha-6 and beta-3Cholinergic receptor nicotinic alpha 6 and beta 3

The receptor functions as a ligand-gated ion channel; upon binding of acetylcholine or exogenous agonists, the channel undergoes a conformational change to allow the influx of cations (primarily Na+ and Ca2+), leading to neuronal depolarization and the subsequent release of neurotransmitters, most notably dopamine in the striatal pathways (Gotti et al., 2010, PubMed).